Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer
Year: 2021
Type: review
Abstract: Diabetes mellitus (DM), is the most common metabolic disease and is characterized by sustained hyperglycemia. Accumulating evidences supports a strong association between DM and numerous lung diseases including chronic obstructive pulmonary disease (COPD), fibrosis, and lung cancer (LC). The global incidence of DM-associated lung disorders is rising and several ongoing studies, including clinical trials, aim to elucidate the molecular mechanisms linking DM with lung disorders, in particular LC. Several potential mechanisms, including hyperglycemia, hyperinsulinemia, glycation, inflammation, and hypoxia, are cited as plausible links between DM and LC. In addition, studies also propose a connection between the use of anti-diabetic medications and reduction in the incidence of LC. However, the exact cause for DM associated lung diseases especially LC is not clear and is an area under intense investigation. Herein, we review the biological links reported between DM and lung disorders with an emphasis on LC. Furthermore, we report common signaling pathways (eg: TGF-β, IL-6, HIF-1, PDGF) and miRNAs that are dysregulated in DM and LC and serve as molecular targets for therapy. Finally, we propose a nanomedicine based approach for delivering therapeutics (eg: IL-24 plasmid DNA, HuR siRNA) to disrupt signaling pathways common to DM and LC and thus potentially treat DM-associated LC. Finally, we conclude that the effective modulation of commonly regulated signaling pathways would help design novel therapeutic protocols for treating DM patients diagnosed with LC.
Source: Advanced Drug Delivery Reviews
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: hybrid
Estimated APC paid: $5,000
Funders: U.S. Department of Defense, U.S. Department of Veterans Affairs, Presbyterian Health Foundation, University of Oklahoma, Oklahoma Center for the Advancement of Science and Technology, Tobacco Settlement Endowment Trust, National Institutes of Health, Stephenson Cancer Center, National Cancer Institute, National Institute of General Medical Sciences
Awards: Cancer Center Planning Grant (P20), G1181589793, G175168911, G1761161551, Non-invasive liquid biopsy approach for using exosomes as a surrogate for determining response to immunotherapy in lung cancer patients, G2277135495, EXOSOMES IN IMMUNOTHERAPY RESISTANCE, G285398573, G3631430387, G3751323388, G4119534169, Mentoring Translational Cancer Research in Oklahoma, G501766673, An improved IL-24 gene-based therapeutic for cancer, HuR Targeted Nanotherapy for Lung Cancer, G5850682332, G5899470782, G627580716, G7930908297, G8166743225, G9000264061, Stephenson Cancer Center - Cancer Center Support Grant
OpenAlex ID: W3190206383